Fig. 1

High expression of BRD4 was associated with poor prognosis and malignancy in GBM. a, b The expression of BRD4 and Chronos dependency score in various tumor cell lines. The BRD4 expression data and Chronos dependency score in tumor cell lines were sourced from the Cancer Cell Line Encyclopedia (CCLE, https://sites.broadinstitute.org/ccle). BRD4 expression levels and Chronos dependency score in GBM cell lines were marked in red. c The expression of BRD4 in clinical GBM patient tissues and normal tissues. Data were sourced from Gene Expression Profiling Interactive Analysis (GEPIA2, http://gepia2.cancer-pku.cn/#index). The red box represented GBM tissue (n = 207), while the gray box represented normal tissue (n = 163). d The expression of BRD4 in GBM patients with different degrees of malignancy. The data was derived from the Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn/index.jsp), where CGGA-325 represented data from the mRNAseq_325 dataset, and CGGA-693 represented data from the mRNAseq_693 dataset. Statistical analysis was performed using ANOVA. e Kaplan-Meier analysis examining the correlation between high or low BRD4 expression and the survival probability of patients with both primary and recurrent GBM. The data was derived from the Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn/index.jsp), where CGGA-325 represented data from the mRNAseq_325 dataset, and CGGA-693 represented data from the mRNAseq_693 dataset